Sichuan Baili Pharmaceutical Co., Ltd.

This early-phase study tests a new drug called BL-B01D1 in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 36 adults aged 18 to 75 will take part.

This early-phase study tests a new drug called GNC-077 in about 20 people with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see early signs of tumor shrinkage. Participants must …

This study tests a new combination of two experimental drugs (SI-B001 and SI-B003) plus standard chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if this mix can shrink tumors or slow the disease. About 60 adu…

This early-phase study tests a new drug called BL-B16D1 in 21 adults with head and neck cancer or other solid tumors that have returned or spread. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participants must have tried st…

This early-phase study tests a new drug called GNC-077 in 20 adults with advanced breast cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive the drug by injection, …

This study tests a new drug called BL-M07D1, given with or without another drug (pertuzumab), compared to standard chemotherapy for HER2-positive breast cancer before surgery. The goal is to see if the new combination can eliminate more cancer cells by the time of surgery. About …

This study tests two experimental drugs, SI-B003 alone or combined with BL-B01D1, in people with advanced bladder cancer or other solid tumors that have not responded to standard treatments. The goal is to see if these drugs can shrink tumors or slow disease progression. About 52…

This study tests two experimental drugs, SI-B003 alone or combined with BL-B01D1, in people with advanced HER2-negative breast cancer that has spread or cannot be removed. The goal is to see if these treatments can shrink tumors or slow the disease. About 58 adults who have not r…

This early-phase study tests a new drug called BL-B01D1 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 570 participants will be enrolled to also see if the drug can shri…

This study tests an experimental drug called BL-M07D1 in women with recurrent or metastatic gynecologic cancers that have a specific marker called HER2. The goal is to find the best dose and see if the drug can shrink tumors. About 138 participants will receive the drug, and rese…

This early-phase study tests a new radioactive drug called Lutetium BL-ARC001 in 22 people with advanced gastrointestinal or other solid tumors that have spread. The main goals are to check safety, find the best dose, and see if it shrinks tumors. Participants must have measurabl…

This study tests three experimental treatments for people with advanced esophageal, stomach, or colorectal cancer that has spread. The goal is to see if these drug combinations can shrink tumors or slow disease progression. About 376 adults aged 18 to 75 will participate, and the…

This phase 3 trial tests whether a new drug, BL-M07D1, works better than the current standard (T-DM1) for people with HER2-positive breast cancer that still has invasive cancer after initial chemotherapy. About 1450 women aged 18-75 will be randomly assigned to receive one of the…

This early-phase study tests a new drug called BL-M17D1 in people with advanced HER2-positive or low-HER2 gastrointestinal cancers and other solid tumors. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 20 adults will take part, …

This early-phase study tests a new drug called BL-M24D1 in 33 adults with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried other tr…

This early-stage study tests a new drug called BL-M14D1 in about 22 people with advanced small cell lung cancer, neuroendocrine tumors, or other solid tumors that have spread and no longer respond to standard treatments. The main goals are to check the drug's safety, find the bes…

This study tests a new drug called BL-M07D1 in people with advanced stomach or gastro-esophageal junction cancer that is HER2-positive and has stopped responding to first-line anti-HER2 therapy. About 490 adults will be randomly assigned to receive either BL-M07D1 or standard che…

This study tests an experimental drug called BL-B01D1 in 38 people with advanced or recurrent gynecological cancers that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must be 18–75 years old and…

This early-phase study tests a new drug called BL-B01D1 in people with advanced stomach or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 96 adults will take part to see if the drug can h…

This study tests a new combination of two drugs (SI-B001 and SI-B003) with or without chemotherapy in people with advanced head and neck cancer that has spread or cannot be removed. The goal is to find the best dose and see if the treatment can shrink tumors. About 130 adults age…

This study tests whether combining two drugs, BL-M07D1 and pembrolizumab, can shrink tumors in people with advanced HER2-positive non-small cell lung cancer. About 80 adults with cancer that has spread or cannot be removed by surgery will receive the treatment. The goal is to see…

This study compares a new drug, BL-M07D1, to standard chemotherapy for people with advanced or spreading non-squamous non-small cell lung cancer that has a specific HER2 gene mutation. About 440 adults will be randomly assigned to receive either the new drug or standard treatment…

This study tests two experimental drugs, BL-B01D1 and SI-B003, given alone or together, in people with head and neck cancer that has come back or spread. The goal is to see if these treatments can shrink tumors or slow the disease. About 186 adults aged 18 to 75 with advanced hea…

This early-phase study tests a new drug called BL-M11D1 in 130 adults whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Participants must have a specific marker (CD33) on…

This early-phase study tests a new drug called BL-M08D1 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it helps shrink tumors. About 22 adults will take part in th…

This early-phase study tests a new drug called GNC-039 in people with advanced solid tumors, including a type of brain cancer called glioma, that have come back or spread. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 60…

This early-phase trial tests a new drug called BL-M24D1 in about 16 people with advanced head and neck cancer or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see early signs of whether the drug shrinks tumors. Participants must…

This early-phase study tests a new drug called BL-B16D1 in 21 adults with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participant…

This early-phase study tests a new drug called BL-M07D1 in people with advanced digestive tract or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 26 adu…

This study tests a new drug, BL-M07D1, against standard chemotherapy in 566 adults with HER2-low breast cancer that cannot be removed by surgery or has spread. The goal is to see if BL-M07D1 can slow cancer growth better than chemo. Participants must be 18-75 years old and have t…

This early-phase trial tests an experimental drug called GNC-035 in 40 adults with non-Hodgkin lymphoma that has come back or stopped responding to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. GNC-035 is a tetra-specific antibody …

This study tests a new drug, BL-B01D1, combined with standard targeted therapy (TKI) and sometimes an immunotherapy (pembrolizumab) for people with advanced kidney cancer that has spread. The goal is to see if the combination shrinks tumors and how safe it is. About 260 adults ag…

This study tests whether adding a new drug, BL-B01D1, to the standard pill osimertinib helps people with advanced EGFR-mutated non-small cell lung cancer live longer without their cancer growing. About 720 adults with this type of lung cancer will be randomly assigned to receive …

This study tests two experimental drugs, SI-B001 and SI-B003, with or without chemotherapy, in people with advanced non-small cell lung cancer. The goal is to find safe doses and see if the combination can shrink tumors. About 160 adults aged 18 to 75 are being enrolled.

This early-stage trial tests a new drug, BL-M07D1, in people with advanced breast cancer or other solid tumors that have a specific protein called HER2. The study aims to find a safe dose and check for side effects. About 26 adults whose cancer has not responded to standard treat…

This early-phase study tests a new drug called BL-M08D1 in 22 adults with blood cancers (lymphoid malignancies) that have returned or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Partic…

This early-phase study tests a new drug called BL-M17D1 in about 20 adults with advanced breast cancer (HER2-positive or negative) or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage. Participants…

This study tests two experimental drugs, BL-B01D1 and SI-B003, alone or together in people with extensive-stage small cell lung cancer that has spread. The goal is to see if these treatments can shrink tumors or control the disease. About 100 adults aged 18 to 75 with good perfor…

This early-phase study tests a new drug called BL-B16D1 in 21 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it helps shrink tumors. Participants receive the drug and…

This study tests a combination of two or three drugs (BL-B01D1, pembrolizumab, and possibly bevacizumab) in people whose cervical or endometrial cancer has come back or spread. The goal is to see if the treatment shrinks tumors or slows the disease. About 96 adults aged 18-75 wit…

This study tests two experimental drugs, BL-B01D1 and SI-B003, alone or together in 130 women with recurrent or metastatic cervical cancer that has not responded to standard treatments. The goal is to see if these drugs can shrink tumors or slow disease progression. Participants …

This early-phase study tests a new drug, BL-M24D1, in people with advanced digestive tract or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 33 adults will take part in this non-randomized tr…

This early-phase study tests a radioactive drug called Lutetium-177 BL-ARC001 in people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 22 par…

This study tests an experimental drug called BL-B01D1 in 76 adults with advanced urinary system or other solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if the drug can shrink tumors. Participants will be monitored for side e…

This study tests a combination of two drugs (BL-B01D1 and a PD-1 antibody) in adults with advanced or spreading non-small cell lung cancer, nasopharyngeal cancer, or other solid tumors. The goal is to see if the combo can shrink tumors and control the disease. About 570 participa…

This study tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced bladder cancer that has not responded to prior treatments. About 508 adults will be randomly assigned to receive either the new drug or a doctor-chosen chemotherapy. The goal is to …

This phase 3 trial tests whether the experimental drug BL-B01D1 works better than standard chemotherapy for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatment. About 384 adults who have had 1-3 prior treatment…

This study tests a new drug called GNC-038, a special antibody that targets cancer from four different angles. It is for people with Non-Hodgkin's lymphoma whose cancer has returned or stopped responding to standard treatments. The main goals are to check the drug's safety, find …

This study tests an experimental drug called BL-M07D1 in people with advanced HER2-positive or low-expressing urinary and digestive tract cancers that cannot be removed by surgery. The first part finds a safe dose, and the second part checks if the drug shrinks tumors. About 42 a…

This study is testing a new two-drug combination (BL-B01D1 + SI-B003) for people with advanced non-small cell lung cancer or nasopharyngeal carcinoma that has spread. The main goal is to see if the treatment is safe and if it shrinks tumors. Researchers will enroll about 121 adul…